Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report: 2013

Research and Markets logo

Dublin, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/ctblpm/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles companies including many key and niche players such as:

  • Baxter International Inc.
  • Beijing Tiantan Biological Products Co. Ltd.
  • Bharat Serums and Vaccines Ltd.
  • Biotest AG
  • China Biologic Products Inc.
  • Guizhou Taibang Biological Products Co. Ltd.
  • CSL Limited
  • CSL Behring
  • Grifols S.A
  • Huanlan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • OMRIX Biopharmaceuticals Ltd.
  • Shanghai RAAS Blood Products Co. Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Key Topics Covered:

I. Introduction, Methodology & Product Definitions

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. Executive Summary

1. INDUSTRY OVERVIEW

  • Intravenous Immunoglobulin - A Proliferating Biologic
  • Outlook
  • Growth Drivers and Challenges
  • All Hopes on IVIg Approval for Alzheimer's of IVIg - Analyzing Pros and Cons
  • Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
  • Subcutaneous IVIg Formulations Gain Therapeutic Foothold
  • Competitive Scenario
  • IVIg Products Offered by Global Leading Players (2012)
  • Octagam Returns to Market with Full Force
  • IVIg Prices to Remain Strong both in the US and Outside the US

2. PLASMA PROTEINS - AN OVERVIEW

  • Plasma Market Witnesses Surging Demand
  • Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

3. IMMUNOGLOBULINS - AN OVERVIEW

  • Overview
  • Per Capita Consumption Rate Varies Across Countries
  • Favorable Reimbursement and High Usage make US the Largest Consumer of Immunoglobulins Worldwide
  • Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
  • IVIg and SCIg: A Face-off!
  • Cost of Product and Treatment
  • Side-Effects
  • Frequency of Treatment
  • Safety Considerations
  • Patient Response to Treatment Varies
  • Site of Care

4. THERAPY OVERVIEW

  • Introduction
  • Intravenous Immunoglobulin
  • Mechanism of IVIg Action
  • IVIg Dosage and Treatment Response Time
  • Complications and Side Effects of Using IVIg
  • Precautions to be Undertaken
  • Intravenous Immunoglobulin - Indications
  • FDA Approved Indications for IVIg
  • Common IVIg Intravenous Dosing Recommendations by Indication
  • Off-Label Usage of IVIg
  • Select Off-Label Indications for IVIg
  • Applications by Medical Specialty
  • Neurology
  • Hematology
  • Immunology
  • Dermatology
  • Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. REGULATORY APPROVALS

  • CSL Behring Obtains EC Marketing Approval for Privigen® for CIDP Patients
  • CSL Behring Obtains FDA Approval for Privigen® to Treat PID and ITP
  • Biotest Pharmaceuticals Obtains FDA Approval for BIVGAM™ IVIg
  • Baxter Obtains EC Marketing Approval for HyQvia
  • Green Cross Receives Approval to Commence Phase III Clinical Trials
  • Baxter Bags FDA Approval for GAMMAGARD LIQUID to Treat MMN
  • Baxter Receives EU Approval for Using KIOVIG to Treat MMN
  • Benesis Bags Regulatory Approval for Extra Indication of Venoglobulin IH
  • CSL Behring Obtains EC Marketing Approval for Hizentra®
  • CSL Behring Secures FDA Approval to Increase Shelf Life of Hizentra
  • Talecris Biotherapeutics Holdings Obtains FDA Approval for Gamunex-C
  • CSL Behring Secures FDA Approval to Increase Shelf Life of Privigen®
  • China includes IVIg on Rural Reimbursement List

6. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Octapharma Canada Introduces Octagam®10% in Canada
  • Biotest Introduces BIVIgAM™ in the US
  • Octapharma USA Re-launches Octagam® 5% Liquid
  • Baxter Unveils GAMMAGARD Liquid 10% Solution in 30g Dosage
  • LFB Biomédicaments Unveils CLAIRYG® Liquid Intravenous Immunoglobulin
  • Grifols Introduces Flebogamma® 10%DIF Intravenous Immunoglobulin
  • Grifols Introduces Niuliva®

7. RECENT INDUSTRY ACTIVITY

  • Octapharma Completes Phase II Clinical Trial of Octagam 10% for Alzheimer's
  • Grifols International Establishes New IVIg Purification Facility in Los Angeles
  • Sorrento Therapeutics Secures Global Rights for Using G-MAB® Antibody Library Technology to Produce rIVIg
  • Momenta Pharmaceuticals Acquires Sialic Switch Assets of Virdante Pharmaceuticals
  • Grifols' AMBAR Study Integrates Therapeutic Plasmapheresis with Alternating Infusion of IVIg and Albumin for Treatment of Alzheimer's Disease
  • Biotest Publishes Clinical Trial Data Related to New Investigational IVIg Product
  • Baxter and Halozyme Therapeutics Publish Results of HyQ Phase III Trials
  • Octagam® Returns to the US Market Following FDA Approval
  • EC Withdraws Suspension of Marketing Authorization for Octagam® and Octagam® 10%
  • Octapharma Obtains Approval for Octagam® Re-supply in Australia
  • Wuhan Institute of Biologic Products and China National Biotech Group Expand Partnership with ProMetic Life Sciences
  • Sao Paulo State Establishes Plasma Fractionation Plant
  • GE Healthcare and Neste Jacobs Forge Partnership to Promote Self-Reliance in Plasma Fractionation Globally
  • ProMetic Life Sciences and Novozymes Enter into Strategic Alliance
  • Abraxis BioScience and ProMetic Life Sciences Ink Collaboration Agreement
  • Grifols Takes Over Talecris

8. FOCUS ON SELECT PLAYERS

  • Baxter International Inc. (US)
  • Beijing Tiantan Biological Products Co., Ltd (China)
  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc (China)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • CSL Limited (Australia)
  • CSL Behring LLC (US)
  • Grifols, S.A (Spain)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • OMRIX Biopharmaceuticals Ltd (Israel)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

9. GLOBAL MARKET PERSPECTIVE

  • Table

III. Market

IV. Competitive Landscape


For more information visit http://www.researchandmarkets.com/research/ctblpm/intravenous

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source:Research and Markets